Cymbalta Pregnancy Risk Fit FDA's New Power To Mandate Post-Market Study

FDA's application of its new ability to require - as opposed to request - post-marketing studies under the FDA Amendments Act is on display in the review of a fibromyalgia claim for Lilly's Cymbalta (duloxetine)